AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04587102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional program(balance exercises and resisted exercises)
Description: balance exercises and resisted exercises
Study NCT00926016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone (Actos)
Description: pioglitazone 45 mg a day
Study NCT03593213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily.
Study NCT04194749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Media Based Physical Therapy
Description: This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
Study NCT04194749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: This intervention is a 12 week therapist supervised clinic-based therapy protocol.
Study NCT00309907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Given IV and subcutaneously
Study NCT00309907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV and orally
Study NCT01190007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caduet
Description: One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
Study NCT00609310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids
Description: Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
Study NCT03966508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation
Description: High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
Study NCT00428519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14 days
Study NCT00428519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant at a dose of 125 mg daily for 14 days
Study NCT00428519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant at a dose of 250 mg daily for 14 days
Study NCT00559286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: application of 80mg or 20mg Telmisartan per day for 30 days
Study NCT00559286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: application of 80mg or 20mg Telmisartan per day for 30 days
Study NCT00534183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine in dose range of 10-20mg
Study NCT00534183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone 1-6mg
Study NCT00534183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 10-20mg
Study NCT02378337 — intervention group
Intervention type: OTHER
Intervention: Image quantify
Description: Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
Study NCT03860532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMPL-011 tablets
Description: Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
Study NCT03860532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMPL-011 capsules
Description: Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
Study NCT01291615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
Study NCT01291615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
Study NCT02529995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 40 mg
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Study NCT02529995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80 mg
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Study NCT02540746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERG Skills Training
Description: Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
Study NCT03548038 — intervention group
Intervention type: OTHER
Intervention: taste test
Description: All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
Study NCT01195974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YASMIN
Description: YASMIN for 21 days
Study NCT01195974 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: YASMIN
Description: YASMIN for 21 days
Study NCT01195974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
Study NCT01195974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken on Days 1 - 10 or Days 12 - 21
Study NCT04373304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low FODMAP diet
Description: A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
Study NCT02429258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farxiga
Description: Farxiga 10mg/day
Study NCT02429258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02429258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin background therapy >/= 1500mg/day
Study NCT02429258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin background therapy >/= 1500mg/day
Study NCT02429258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin >/= 30 units
Study NCT02429258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin >/= 30 units
Study NCT02723266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOPPING-GDM
Description: Educational counseling and skills building Intervention
Study NCT01828710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Myo-inositol normospermic
Description: 4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
Study NCT01828710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol OAT
Description: B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
Study NCT01828710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid normospermic
Description: Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B
Study NCT04167176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
Study NCT04167176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Port site infiltration
Description: After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
Study NCT04167176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)
Description: Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
Study NCT04167176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: Bupivacaine 0.5% will be included in the injected LA mixture.
Study NCT02540746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Three week Motivational Enhancement group
Study NCT04167176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: Lidocaine 2% will be included in the injected LA mixture.
Study NCT04194684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
Study NCT01582984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video or education session in addition to standard consent
Description: Video added to standard consent + handout Video + education session added to standard consent + handout
Study NCT01582984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video or education session in addition to standard consent
Description: Video added to standard consent + handout Video + education session added to standard consent + handout
Study NCT01202071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 5 mg Tablets
Description: Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast.
Study NCT01202071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 10 mg Tablets
Description: Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast.
Study NCT01202071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 20 mg Tablets
Description: Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast.
Study NCT01202071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)
Description: Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, >=2 hours after the completion of breakfast.
Study NCT02172482 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide18 micrograms (capsule with powder for inhalation)
Study NCT03265067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC
Description: Application of the autoRIC device
Study NCT01000493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: Neurokinin-1 (NK-1) antagonist
Study NCT01000493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo to match orvepitant 60 mg dosage form
Study NCT01988168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture closure
Description: A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
Study NCT01988168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staples closure
Description: Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
Study NCT04707586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
Study NCT02856009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of a quality of life questionnaire
Study NCT01905709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human fecal matter
Study NCT04487444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Synthetic 28 amino acid peptide identical to naturally circulating compound
Study NCT03180229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron 1 Mg/mL Intravenous Solution
Description: 1 milligram (mg) will use on group Granisetron before 5 min induction
Study NCT03733327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
Study NCT00387920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT00387920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00387920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT00387920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02221908 — intervention group
Intervention type: DEVICE
Intervention: Mespere Venus 1000 CVP System
Study NCT03201679 — intervention group
Intervention type: PROCEDURE
Intervention: Repair of hip fracture
Description: Patients undergoing hip fracture surgery
Study NCT03733327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT03261479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal image
Description: We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B
Study NCT00625898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B
Study NCT03733327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Etoposide was administered at 15 mg/kg/day on days -3 to -2.
Study NCT03426527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
Study NCT03426527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine-Dexmedetomidine
Description: Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
Study NCT01674647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
Study NCT03426527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Anaesthesia
Description: Using propofol, fentanyl and atracurium
Study NCT03426527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anaesthesia
Description: Using propofol, fentanyl and atracurium
Study NCT02408627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Study NCT02408627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Study NCT01988077 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adoptive cell transfer
Description: Adoptive cell transfer